Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment

Sharma, Ajay; Paliwal, Geetanjali; Upadhyay, Nisha; Tiwari, Archana

doi:10.1186/s40200-016-0256-4

Cited by 3 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For several decades, hyperglycaemia was considered to arise from the poorly defined phenomenon of insulin resistance coupled with the immunological or biochemical toxicity to insulin‐secreting beta cells in the pancreas, manifesting as beta cell failure. More recently these have been joined by abnormalities of the incretin system, evident as the reduced effect of glucagon‐like peptide‐1 (GLP‐1), glucose‐dependent insulinotropic peptide (GIP) and related proteins . These factors are encompassed in the diseases of diabetes, most prominently the autoimmune disease of type 1 diabetes, the obesity and metabolic disease of type 2 diabetes and the hyperglycaemia of pregnancy, including gestational diabetes mellitus (GDM)…”

Section: Introductionmentioning

confidence: 99%

“…Over the last few decades, the efficacy of treating hyperglycaemia with available agents to prevent macrovascular diseases has been variable and remains a subject of considerable controversy. An improved understanding of the unique mechanisms of action of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and GLP‐1 agonists is encouraging research into their cardiovascular benefits and igniting hopes for a revolution in the treatment of diabetes …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The emerging role of metformin in gestational diabetes mellitus

Gray

McGuire

Cohen

et al. 2017

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Metformin use during pregnancy is controversial and there is disparity in the acceptance of metformin treatment in women with gestational diabetes mellitus (GDM) in Australia. Despite short term maternal and neonatal safety measures, the placental transfer of metformin during GDM treatment and the absence of long-term safety data in offspring has regulators and prescribers cautious about its use. To determine the current role in GDM management, this literature review describes the physiological changes that occur in GDM and other forms of diabetes in pregnancy (DIP) and international changes in guidelines for GDM diagnosis. Management options are considered, with a focus on the evolving evidence for metformin, its mechanism of action, the maternal, foetal and neonatal outcomes associated with its use and benefit vs risk when compared with the current gold standard, insulin. Investigation reveals a favourable balance of evidence to support the safety and long-term benefits, to mother and child, of using metformin as an alternate to insulin for treatment of GDM. Recent findings of the gastrointestinal-directed action of metformin are at least as important as the hepatic effect and the availability of a novel delayed-release metformin dose form to exploit this new information provides a product and therapeutic strategy ideally suited to the use of metformin in GDM.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The emerging role of metformin in gestational diabetes mellitus

Gray

McGuire

Cohen

et al. 2017

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Another physiological substrate of DPP4 is glucose-dependent insulin polypeptide (GIP), also known as incretin, and the level of GIP increases with inhibition of DPP4 activity [ 35 , 36 ]. Similar to GLP-1, GIP enhances insulin secretion in pancreatic beta cells in a glucose-dependent manner but appears to act in a different way on glucagon secretion [ 37 , 38 ].…”

Section: Dpp4 and Dpp4 Inhibitions In Diabetesmentioning

confidence: 99%

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment

Yin

Wang

et al. 2022

Molecules

View full text Add to dashboard Cite

In recent years, important changes have occurred in the field of diabetes treatment. The focus of the treatment of diabetic patients has shifted from the control of blood glucose itself to the overall management of risk factors, while adjusting blood glucose goals according to individualization. In addition, regulators need to approve new antidiabetic drugs which have been tested for cardiovascular safety. Thus, the newest class of drugs has been shown to reduce major adverse cardiovascular events, including sodium-glucose transporter 2 (SGLT2) and some glucagon like peptide 1 receptor (GLP1) analog. As such, they have a prominent place in the hyperglycemia treatment algorithms. In recent years, the role of DPP4 inhibitors (DPP4i) has been modified. DPP4i have a favorable safety profile and anti-inflammatory profile, do not cause hypoglycemia or weight gain, and do not require dose escalation. In addition, it can also be applied to some types of chronic kidney disease patients and elderly patients with diabetes. Overall, DPP4i, as a class of safe oral hypoglycemic agents, have a role in the management of diabetic patients, and there is extensive experience in their use.

show abstract

“…Patients with type 2 diabetes express higher levels of the DPP‐4 protein and increased enzymatic activity in the blood and tissues than healthy controls . Moreover, DPP‐4 cleaves incretins, a group of metabolic hormones that includes glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) . Additionally, DPP‐4 is widely expressed in T and B cells, natural killer cells, subsets of macrophages and hematopoietic progenitor cells, as well as in the epithelial cells, endothelial cells and keratinocytes of a variety of tissues .…”

Section: Introductionmentioning

confidence: 99%

A dipeptidyl peptidase‐4 inhibitor promotes wound healing in normoglycemic mice by modulating keratinocyte activity

Shih

Huang

et al. 2018

Experimental Dermatology

View full text Add to dashboard Cite

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a well-known and novel class of oral antihyperglycaemic drugs. DPP-4 inhibition facilitates ulcer healing in patients with diabetes. However, the actual mechanisms, which are independent of lower blood glucose levels, are still unknown. Therefore, the aim of this study was to analyse the effect of the DPP-4 inhibitor sitagliptin on wound healing through a glucose-independent pathway. In this study, DPP-4 inhibitors facilitate keratinocyte differentiation and the proliferation, increase blood flow in the cutaneous of wounds in healthy C57BL/6 mice. Additionally, the administration of the DPP-4 inhibitor ameliorates wound healing and enhances adiponectin expression in healthy C57BL/6 mice. Taken together, our results reveal a protective role for the DPP-4 inhibitor sitagliptin in wound healing by regulating adiponectin and phospho-eNOS levels in keratinocytes. Based on these results, the DPP-4 inhibitor may have therapeutic potential for healing wounds through a diabetes-independent mechanism.

show abstract

Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment

Cited by 3 publications

References 3 publications

The emerging role of metformin in gestational diabetes mellitus

The emerging role of metformin in gestational diabetes mellitus

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment

A dipeptidyl peptidase‐4 inhibitor promotes wound healing in normoglycemic mice by modulating keratinocyte activity

Contact Info

Product

Resources

About